Growth Hormone Research Market

Ipamorelin

A ghrelin-mimetic growth hormone secretagogue often paired with CJC-1295 in research-market discussions.

Growth HormoneSecretagogueGhrelin Mimetic

Also appears in: Muscle Growth

Price compare
106 tracked offers across 106 vendors · 22 dosages
Best trust-adjusted value: Peptide Plugs · Strong trust · $1.80/mg
From
$1.80/mg
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Growth Hormone

Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 2 trials · 49 PubMed results

Promising
Research evidence

Ipamorelin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Ipamorelin has 2 name-matched clinical trials (highest phase: Phase 2) and 49 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 2
Trial quality
Large RCT
Outcomes
Surrogate / early
Replication
Multiple trials
Literature
High-impact
PHASE2 · Randomized Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function PHASE2 · Randomized Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus European Journal of Endocrinology · 96 citations Ipamorelin, the first selective growth hormone secretagogue Drug Testing and Analysis · 49 citations Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP‐1, GHRP‐2, GHRP‐6, Hexarelin, and Ipamorelin Journal of Medicinal Chemistry · 34 citations A New Series of Highly Potent Growth Hormone-Releasing Peptides Derived from Ipamorelin Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What ipamorelin is

Ipamorelin is a growth hormone secretagogue that is usually discussed as a ghrelin-mimetic peptide. It commonly appears in the same conversations as CJC-1295 because the two are frequently described together in growth-hormone optimization stacks.

Why it matters

It is one of the most recognizable non-approved entries in the growth-hormone peptide category, so it helps anchor the library for readers trying to understand that corner of the market.

Regulatory context

Ipamorelin is not FDA-approved as a peptide medicine in the United States. On PeptideBenchmark it is categorized as research-market, not approved therapy.

Practical reading note

If a page talks about ipamorelin as if it were standard wellness medicine, that is usually a sign the regulatory context is being blurred.